Duo Xu, Miranda Wang, Selene Peng

Duo Xu, Miranda Wang and Selene Peng are consultants with experience across diverse therapeutic areas, and recent experience on NRDL and innovative access options in China.


China 2021: The NRDL Readout

China‘s 2021 National Reimbursement Drug List (NRDL) results are finally out, and this year features another major expansion of the NRDL formulary, with ongoing emphasis on innovations and some much anticipated breakthroughs in rare disease drug inclusions.

Maximizing China Access for Innovative Therapies

To maximize the potential of innovative therapies in the Chinese market, it’s important to have a holistic view of the full range of options and levers, prioritize and sequence the ones with the highest impacts, and develop an integrated strategy tailored to address the country’s unmet needs.